Navigation Links
Noted Vertebroplasty Expert Cites Concerns About Recently Published Study
Date:8/11/2009

Dr. Mubin Syed evaluates findings; calls for additional research

DAYTON, Ohio, Aug. 11 /PRNewswire/ -- A new study by Mayo Clinic researchers has given rise to more questions than answers about the effectiveness of vertebroplasty to treat osteoporotic spinal fractures.

Vertebroplasty is a widely used procedure in which medical cement is injected into vertebrae to relieve pain and improve mobility in patients who have osteoporotic fractures. This study, funded by the National Institutes of Health, was the first of its kind, using a double-blinded research model to examine the impact of vertebroplasty. It was published last week in The New England Journal of Medicine to mixed reviews by the medical community.

"This was an extremely interesting study, but the results are far from conclusive due to several weaknesses in the method used. Additional research is definitely indicated," said Dr. Mubin I. Syed, a neuroradiologist and diagnostic, interventional and vascular radiologist.

One major issue cited by Dr. Syed was the small size of the study group. To demonstrate statistical differences between groups requires that the research team enroll enough patients for the statistics to have meaning. The original group size for the Mayo Clinic study was to be 250 patients. Due to difficulties in recruiting participants, the final group size was reduced to 131 people, nearly half of the original design.

"This is important," explained Dr. Syed, "because the trends in the data show that if the study had enough patients, the group receiving vertebroplasty could have demonstrated a clinically meaningful improvement in pain. It is therefore surprising that a study that was showing a trend toward statistical significance was terminated early with only half the number of patients recruited. A huge doubt now remains as to whether a study with the original intended group size would have yielded a different outcome."

Additionally, selection bias could have also played a large part in the study's results. "Only 131 out of 431 (30.4 percent) eligible patients elected to participate, increasing the potential for selection bias," noted Dr. Syed.

A third issue was the crossover rate for patients who received the control or "placebo" procedure. Patients in the trial were able to "cross over" and get the other treatment after one month.

"Even though they had no confirmation of which treatment they received, nearly four times as many patients or 43 percent who had the control treatment crossed over to have vertebroplasty performed, compared to 12 percent of vertebroplasty patients who switched," said Dr. Syed.

The final issue to consider is that the control procedure included injecting 0.25 percent of bupivicaine into the periosteum of the pedicles. "The problem," explained Dr. Syed, "is that this resembles a medial branch block for the treatment of facet-related pain. The duration of relief following medial branch block is variable, but may last for several weeks."

He added that many patients with compression fractures have concurrent facet-related pain due to stress on the facet joint as a result of the fracture.

"I applaud Dr. Kallmes for his work. His study is very interesting, but I don't think it's conclusive. Additional research is needed to truly assess the efficacy of vertebroplasty," said Dr. Syed.

Dr. Syed is on staff at Good Samaritan Hospital and Dayton Heart Hospital in Dayton. He is also a founding partner of Dayton Interventional Radiology. In addition, Dr. Syed has participated in clinical trials and published several papers on vertebroplasty.


'/>"/>
SOURCE Dr. Mubin I. Syed
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Signs of Depression Noted in Second Graders
2. UPDATE: Swine Flu Spread Will Trigger Difficult Legal Questions for Employers Says Noted Pillsbury Attorney
3. Swine Flu Plans Triggering Difficult Legal Questions, Says Noted Pillsbury Attorney
4. Kouros Azar, M.D. (doctorazar.com), Noted Plastic and Reconstructive Surgeon, Offers Top 10 Tips to Patients to Help Celebrate National Patient Safety Awareness Week
5. Noted State Government Medical Director Dr. Stephen Saunders To Join APS Healthcare
6. Three Noted Women of Valor to be Honored at Los Angeles Jewish Home Gala Dinner
7. 4th annual Templeton-Cambridge fellowships awarded to 10 noted journalists
8. Noted Litigator Peter Diedrich Joins Musick Peeler & Garrett LLP
9. 39 Noted Performing Artists Urge Congress to Fix Flaws in Presidents Global AIDS Plan
10. Los Angeles Jewish Home Support Group Continues High-Profile Speaker Program With Noted Legal Scholar and Expert Laurie L. Levenson
11. Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading: Studies Actually Show it is Effective at Reducing Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology: